Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YMI024 in stable coronary artery disease with elevated hsCRP
2026-525974-21-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis, heart failure (HF) and chronic kidney disease (CKD) comparing YMI024 with Placebo (2 arms). Primary endpoint: Change from baseline in log-transformed IL-6 (primary). Planned start Sep 2026; status: authorised.
02
Drugs
YMI024
03
Conditions
coronary arteriosclerosisheart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2026-525974-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525974-21-00.